We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.

Ocular Therapeutix (NASDAQ:OCUL) stock rises as Needham rates the company a new Buy, citing the potential of its lead candidate, Axpaxli. Read more here.

REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm ...

The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. . Shareholders who purchased ...

NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Regeneron's issues in the past ...

The United States Court of Appeals for the First Circuit recently joined the Sixth Circuit (2023) and Eighth Circuit (2022) ...

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...

Ocular Therapeutix's Axpaxli targets wet AMD with long-acting treatment. Click here to find out why OCUL stock is a Strong ...

The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...